amarin's ip value just increased by 100's of millions, if not billions. where is the appropriate market cap adjustment?

There are calculatable treble damages now.

Recall their generic product due to legal jeopardy.
If the retailers continue their generic sales, they could in turn be implicating themselves in further infringement.

By not selling more generic icosapent ethyl in the interim until the legal case is settled.
More generic sales means more damages if amarin wins ...

Wouldn't prudent risk management on hikma's (as well as other generics) suggest that they immediately seek to limit possible additional treble damages by ceasing/limiting additional generic sales until then legal outcome is determined?

https://www.nasdaq.com/market-activity/institutional-portfolio/sarissa-capital-management-lp-907328

PREPARE
https://clinicaltrials.gov/study/NCT04216251?tab=table

From last friday

17:28:47 $1.32 1,315,200
17:28:47 $1.32 285,200

Is it a pattern yet?
1,375,361 @ 1.35 AH today

That is strange, that 1.5M shares would be available for sale after regular trading hours.

14,426 × 1.09. Mr. Holt

Where did you note this $1 limitation?

Share repurchase program in 2024

Trading halt at 10% move?

High volume, large 10k trades. Price appreciation.
Feels like news pending ...

0.6 million (600k) shares outstanding ... And 10M shares traded. What's going on?

LAVAL, QC, Aug. 22, 2023 /CNW/ - Neptune Wellness Solutions Inc. ("Neptune" or the "Company") (NASDAQ: NEPT), a consumer-packaged goods company focused on plant-based, sustainable and purpose-driven lifestyle brands, announced today that it will conduct a share consolidation of its outstanding common shares ("Common Shares") on the basis of one (1) post-consolidation Common Share for every forty (40) pre-consolidation Common Shares (the "Consolidation"). The Consolidation was previously approved by the board of directors of the Company on August 7, 2023. Each fractional Common Share remaining after completion of the Consolidation that is less than one (1) whole of a Common Share will be increased to one (1) whole Common Share. The Consolidation will reduce the number of Common Shares issued and outstanding from approximately 24.1 million Common Shares to approximately 0.6 million Common Shares.

No, just vascepa. No statin.

I blame 10 years of vascepa!

Total coronary calcium score: 0

Coronary artery calcification is a mark of atherosclerosis and the higher the score, the greater the risk of coronary events. The area of atherosclerotic plaque is greater than the calcified component. Coronary calcium scores are highly sensitive for the presence of atherosclerosis but have a lower specificity for coronary artery disease. Coronary calcium scores outperform other conventional risk factors and risk scoring methods in identifying patients at risk for future coronary events. A score of 0 implies a low, but not zero, likelihood of coronary artery disease events; a score of 0 has a 98% negative predictive power.

Holt bought the required 300,000 shares today

Posed an interesting question:

https://www.medscape.com/s/viewarticle/994149?ecd=wnl_edit_tpal_etid5705510&uac=124879MJ&impID=5705510

https://www.medscape.com/s/viewarticle/992783?ecd=wnl_edit_tpal&uac=124879MJ&impID=5597652

"there were present or represented by proxy an insufficient number of shares of the Company’s outstanding shares of voting stock to constitute a quorum for the purposes of the marketplace rules of the Nasdaq Stock Market."

Very interesting ... How will they overcome this nonvoter problem?

Why the rush to buy (4 20k trades) in the pre market?

From initial discovery to the marketplace takes about 10 to 15 years for a new medicine.

Each 5,000 to 10,000 compounds that enter to the pipeline, only 1 receives approval.

Medicines that reach clinical trials have only a 16% chance of being approved.

The average R&D investment for each new medicine is around $1.2-1.5 billion, including the cost of failures.

https://www.cnbc.com/2023/05/16/google-cloud-launches-ai-tools-to-accelerate-drug-discovery.html?__source=androidappshare

In its petition for certiorari, Teva asks ”can the generic manufacturer be held liable on a theory that its label still intentionally encourages infringement of those carved-out uses?”  Teva asserts that the Federal Circuit’s decision “eviscerates the key element of inducement liability:  the requirement that a plaintiff prove active steps to encourage direct infringement”, arguing that the decision “effectively nullifies a Congressional enactment created specifically to encourage precisely what Teva did here: bring a low-cost generic drug to market labeled for unpatented uses.”  In opposition, GSK’s question presented was slightly different: “When a generic drug is doubly indicated for a patented use, and there is strong record evidence of intent and inducing conduct, can the generic manufacturer evade liability for induced patent infringement merely because it did not include on its label (i.e. ‘carved out’) one of the two indications corresponding to the patented use?”

https://www.jdsupra.com/legalnews/previewing-generic-s-skinny-label-7905330/

I gave you credit. You always talk in favor of your current position.

So no percentage of ongoing sales?

https://time.com/6256674/covid-19-affects-heart/

Ok mister 10k transaction is back in force today

Amarin leadership doesnt seem to understand that the non-employee shareholders want vascepa and amarin's IP in ALREADY well-funded BP hands.

Wait.
Doesn't a shareholder majority vote to remove wold-olsen as chairman also remove him as a board member?

Sarissa called to dismiss current director Per Wold-Olsen, chairman of board (-1)
and to appoint to the board of directors the investor's nominees,
1 Patrice Bonfiglio,
2 Paul Cohen, M.D.,
3 Mark DiPaolo Esq.,
4 Keith Horn,
5 Odysseas Kostas M.D.,
6 Louis Sterling III
7 and Diane Sullivan

current board of directors
1 Adam Berger
2 Erin Enright
3 Jan van Heek (since 2010)
4 Karim Mikhail
5 Geraldine Murphy
6 Kristine Peterson (since 2010)
7 Murray Stewart
8 Alfonso Zuleta

leaving 7 votes aligned with denner's agenda vs. 8 entrenched votes against, tell me, what i am missing?

Amarin has also continued to progress our fixed-dose combination (FDC) program for icosapent ethyl, securing the future durability of our VASCEPA/VAZKEPA franchise ** in Europe **.


So, not in the US?

Tailwinds if this volume continues all day

I dont see a date.
And replace COB, but add not replace other directors.
would become a 15 member BOD.

Amarin Announces Preliminary (Unaudited) Fourth-Quarter and Full-Year 2022 Revenues and Cash Position

Revenues: For the fourth quarter and full year 2022, Amarin estimates total net revenue, subject to audit, to be between $88 to $90 million and $367 to $369 million, respectively. These results continue to reflect ongoing stabilization of the U.S. business for VASCEPA® (icosapent ethyl).

Cash Position: Amarin ended 2022 with approximately $310 million in cash and investments, with positive cash flow of approximately $4 million in the fourth quarter of 2022.

On December 26, 2022, Amarin Corporation plc (the “Company”) entered into a Settlement Agreement (the “Settlement Agreement”) with Health Net, LLC that resolves previously disclosed patent infringement litigation in the U.S. District Court in Delaware. The specific terms of the settlement are confidential. The Company is pleased with the outcome and believes entering into the Settlement Agreement will provide significant value in the market with payors.

The Company will continue to vigorously defend its intellectual property rights related to VASCEPA.

What's with all the 5 digit trades?

I would also add, the recommended daily dosage is enormous compared to other preventative drugs, e.g., statins.

Speculation from someone who ritually watches AMRN level2 bid/ask throughout the day, every day.
Baker bros was selling every time AMRN reached (and exceeded) $1.20.
Curious to see how AMRN reacts now with baker bros overhead selling out of the way.